Two related editorials and a “Perspective” article discuss the finding of this study, indicating that it supports pharmacotherapy decisions based on absolute risk levels, in a similar way to current recommendations for lipid lowering. For people at high cardiovascular risk, a systolic goal of less than 120 mm Hg is appropriate. Substantial effort and resources will be required: initial combination therapy was the norm in SPRINT, with monthly visits until blood pressure was at the target level.